Researchers are focusing on a significantly larger area of the brain than previously thought as potentially crucial in the development of Parkinson’s disease, offering a recent avenue for treatment development. The findings center on the somato-cognitive action network, a complex network involved in movement and cognitive function.
Parkinson’s disease, a progressive neurodegenerative disorder, currently affects approximately 200,000 people in France, with around 25,000 new cases diagnosed annually. Even as existing treatments can manage symptoms, they do not halt the disease’s progression. The condition is primarily characterized by the destruction of dopamine-producing neurons, impacting motor control. Dopamine is a neurotransmitter essential for communication between neurons.
Traditionally, research has concentrated on the substantia nigra, a region within the brain responsible for dopamine production. Even though, emerging research suggests a broader network plays a critical role. The somato-cognitive action network integrates sensory and motor information, influencing movement planning and execution. Scientists believe changes within this network contribute to both the motor and non-motor symptoms experienced by Parkinson’s patients, including sleep disturbances, blood pressure regulation issues, and difficulties with gait.
The role of alpha-synuclein, a protein that forms abnormal structures in the brain, has been established in triggering neurodegeneration in Parkinson’s disease. However, the precise causes remain unclear, with scientists hypothesizing a combination of genetic predisposition and environmental factors, such as exposure to pesticides, contribute to the disease’s onset. Age is a significant risk factor, with a noticeable increase in prevalence after age 70. Men are more likely to be diagnosed than women, with a ratio of two men to one woman after the age of 40.
Approximately 5% of Parkinson’s cases are familial, indicating a hereditary component, and 13 genes have been identified as potentially causative. The majority of current treatments focus on symptom management rather than slowing disease progression.
